What is Qoolabs?
Qoolabs Inc. is a distinguished entity in the biotechnology landscape, specializing in the provision of rabbit monoclonal antibody services. Their core competency lies in the innovative QMAb technology, which facilitates the rapid development of high-quality antibodies derived from rabbit peripheral blood mononuclear cells. This advanced methodology ensures exceptional specificity and sensitivity, crucial for applications spanning research, diagnostics, and therapeutic development. The company's comprehensive product portfolio includes custom rabbit monoclonal antibodies, lateral flow rapid tests, proteins, and assay kits, designed to empower scientific endeavors and streamline the antibody creation process for challenging targets.
How much funding has Qoolabs raised?
Qoolabs has raised a total of $66K across 1 funding round:
Debt
$66K
Debt (2021): $66K with participation from PPP
What's next for Qoolabs?
With the recent influx of substantial expansion capital, Qoolabs is poised to amplify its operational capacity and market reach. The company's strategic focus will likely involve scaling its QMAb technology platform, enhancing its research and development pipeline, and potentially expanding its service offerings to address unmet needs in diagnostic and therapeutic antibody development. This financing at a significant Series B/C stage suggests a trajectory towards broader commercialization and strategic partnerships, aiming to solidify its position as a leader in specialized antibody services.
See full Qoolabs company page
